



ICTRP Registry Profile

Clinical Trials Registry India (CTRI)





Basic Information

I.	Name of person completing this form	Dr H.K.Chaturvedi
II.	Role of the person completing this form	Director Incharge ICMR-NIMS and Administrator - CTRI
	(that is, the role of this person in the registry making this application)	
III.	Date this form was completed	27/09/2023
IV.	Signature of person completing this form	Dr H K Chaturvedi
V.	Official Name of Registry (list abbreviation used, if relevant) Eg Australian and New Zealand Clinical Trials Registry (ANZCTR)	Clinical Trials Registry India (CTRI)
VI.	Registry postal address	Clinical Trials Registry India ICMR-National Institute of Medical Statistics Ansari Nagar New Delhi
VII.	Registry street address (if different to postal address)	Clinical Trials Registry India ICMR-National Institute of Medical Statistics Ansari Nagar New Delhi
VIII.	Registry URL (Registry's web site address)	https://www.ctri.nic.in/
IX.	Registration URL (Web site where users go to register a trial)	https://ctri.nic.in/Clinicaltrials/login.php
X.	Application type	Application for Primary Registry status □
		Application for Partner Registry status □
XI.	What is the name of the agency (or agencies) that funds the registry?	Indian Council for Medical Research (ICMR)
XII.	What is the name of the agency that manages the registry?	ICMR-National Institute of Medical Statistics (NIMS)





AIII.	Advisory Board? *	Yes No	
XIV.	If the registry has an Advisory Board, please describe its terms of reference, which organizations are represented on the Board, and how often it meets. If necessary, please attach this information to the application as a separate document.	Yes, we have the CTRI so committee meetings on regular that List of Members attached in the	intervals.
XV.	Is registration of a clinical trial a legal requirement in the country (or countries) covered by the registry? *	Yes No ⊠ □	
	If yes, please provide the title of the relevant law and information on how a copy of the law can be obtained (including the relevant web address)	Schedule Y Drugs and Cosmetic Drug Controller General India ma CT New Rules 2019	
XVI.	Is registration of a clinical trial a requirement to obtain ethics approval in the country (or countries) covered by the registry? *	Yes No ⊠ □	
	If yes, please provide the title of the relevant document describing this requirement and information on how this document can be obtained (including the relevant web address)	Ethics Committee approval Docu DCGI DOCUMENT to be uploade	
XVII.	Is the registry currently accepting clinical trials for registration?	Yes No □	
XVIII.	How many trials are on your da	tabase?	
On 27/	09/2023 there were 58106 trials	on the registry database.	
directly b		rimary Registry status until it contains at leas ptable for a registry to only include trial inform	
XIX.	Does the registry agree in princ International Standards for Clin		Yes No ⊠ □





1.1. The Registry will accept prospective registration of interventional clinical trials submitted by Responsible Registrants

1.1.1. Does the Registry register trials before the first participant has been recruited?	Yes	No
	\boxtimes	
a) Does the Registry query submissions where registration is being	Yes	No
sought after the first participant has been recruited?	\boxtimes	
b) Does the Registry make it clear to Responsible Registrants that	Yes	No
prospective registration means that a trial must complete the registration process, <u>and</u> have a trial registration number issued, <u>before</u> the recruitment of the first participant.	×	
1.1.2. Does the Registry register trials that have already recruited the first	Yes	No
participant? (Also referred to as retrospective registration)		\boxtimes
1.1.3. Does the Registry register other types of studies, including	Yes	No
observational studies	\boxtimes	
1.1.4. Does the Registry register all trials submitted by Responsible	Yes	No
Registrants	\boxtimes	
a) Does the Registry accept trials submitted by Responsible Registrants?	Yes	No
	\boxtimes	
b) Does the Registry ask the person submitting a trial for registration to	Yes	No
verify that they meet the terms and conditions for being a Responsible Registrant before being able to proceed to trial registration.	\boxtimes	
c) Does the Registry use the contact details provided by the Responsible	Yes	No
Registrant to verify that those details are correct?	\boxtimes	
d) As a minimum, Registries must send an email to the address given and	Yes	No
receive a reply from that same address. When possible, the telephone number and/or surface mail address will also be verified in a similar	\boxtimes	
fashion.		
e) Does the Registry ensure that all Responsible Registrants are	Yes	No
associated with an institution or organization?	\boxtimes	
f) Does the Registry obtain institutional contact details for the	Yes	No
Responsible Registrant, including name and telephone number of the institution?	×	
1.1.5. Does the Registry accept studies for registration when the data is	Yes	No
submitted as an electronic data file (eg as an xml file)		\boxtimes
Note: This is not a requirement and is being asked for information only.		





1.2. The registry will be open to all prospective registrants (either internationally or within one or more specific countries) (ICMJE requirement)

a) Which types of study does the Registry accept for registration? (tick all	that apply)	
☐ Interventional studies- Yes		
☐ Observational studies- Yes		
b) If registration is restricted in some way (eg only accepts trials from a particular health care condition (eg cancer) or intervention) pleasit is restricted:		
Accepts trials only from India and countries that do not have a poor of their own, not from countries that have their own registry	imary registry	
c) From which countries does the Registry accept trials for registration		
India and countries that do not have a primary or partner registr like Bangladesh, Malaysia, Pakistan, Indonesia etc.	y of their own	
1.3. The Registry will be able to collect and publicly display the WHO Tria Data Set (TRDS) (ICMJE requirement).	I Registration	
 Does the Registry collect and display, on a publicly accessible web site, all of the items in the WHO Trial Registration Data Set 	Yes No □	
b) Does the Registry have quality control procedures in place to ensure all items in the TRDS contain meaningful data?	Yes No ⊠ □	
 c) Does the Registry collect the optional TRDS data items? If yes, please specify: Ethics Committee Approval document, Regulatory document. 	Yes No ⊠ □	
1.4. The Registry will make an effort to keep registered information up-to-	date.	
a) Does the Registry permit Responsible Registrants to update information about their trial?	Yes No ⊠ □	
 b) Does the Registry have a reminder system to facilitate the submission of updated information by the Responsible Registrant. 	Yes No □	
If yes, please state how often the Registry reminds Responsible Registrants to update their data (eg once every 6 months; once every year):		
Every six months, the registrant is sent a follow up mail to update trial records Note: This is not a requirement and is being asked for information only.		
c) Does the Registry display the date the trial record was last updated?	Yes No	
Note: This is not a requirement and is being asked for information only.		





a)	least annually until the Registrant has recorded meaningful information about the publication of the trial results (e.g. has listed a citation in a "Publications" field)?	Yes	No ⊠
	is is not a requirement and is being asked for information only. e Registry will <u>never</u> remove a trial once it has been registered.		
a)	Does the Registry ever delete a trial record from their database, or remove it from public view, once a registration number has been issued?	Yes	No ⊠
del	please explain the circumstances under which a record would be eted:		
b)	Does the Registry inform Responsible Registrants at the time of registration that a trial cannot be deleted once it has been registered?	Yes ⊠	No □
c)	Does the Registry have clear and transparent processes for dealing with requests to remove a trial record from public view, and have these processes been documented in the SOPs?	Yes ⊠	No □
~ ~			
2.1. Th	uality and Validity e Registry will have processes in place to make sure that registered ete and accurate.	l data	is
2.1. Th	e Registry will have processes in place to make sure that registered ete and accurate. Do Registry staff routinely check all data submitted about a trial for completeness and meaningfulness to ensure that all TRDS fields are populated and comply with the minimum standards?	I data Yes ⊠	is No □
2.1. Th	Do Registry staff routinely check all data submitted about a trial for completeness and meaningfulness to ensure that all TRDS fields are populated and comply with the minimum standards? If one or more items in the TRDS submitted for registration are incomplete or not meaningful, do Registry staff contact the Responsible Registrant and attempt to obtain complete and meaningful data?	Yes	No
2.1. Th comple	e Registry will have processes in place to make sure that registered ete and accurate. Do Registry staff routinely check all data submitted about a trial for completeness and meaningfulness to ensure that all TRDS fields are populated and comply with the minimum standards? If one or more items in the TRDS submitted for registration are incomplete or not meaningful, do Registry staff contact the Responsible Registrant and attempt to obtain complete and meaningful data? Does the Registry's database system apply automated checking procedures (e.g. range checks, logic rules) to data items to facilitate validity checking?	Yes ⊠ Yes	No □ No
a)	e Registry will have processes in place to make sure that registered ete and accurate. Do Registry staff routinely check all data submitted about a trial for completeness and meaningfulness to ensure that all TRDS fields are populated and comply with the minimum standards? If one or more items in the TRDS submitted for registration are incomplete or not meaningful, do Registry staff contact the Responsible Registrant and attempt to obtain complete and meaningful data? Does the Registry's database system apply automated checking procedures (e.g. range checks, logic rules) to data items to facilitate	Yes ⊠ Yes ⊠ Yes	No □ No □ No
a) b)	Do Registry staff routinely check all data submitted about a trial for completeness and meaningfulness to ensure that all TRDS fields are populated and comply with the minimum standards? If one or more items in the TRDS submitted for registration are incomplete or not meaningful, do Registry staff contact the Responsible Registrant and attempt to obtain complete and meaningful data? Does the Registry's database system apply automated checking procedures (e.g. range checks, logic rules) to data items to facilitate validity checking? Does the Registry have processes in place for deciding whether to register trials where the Responsible Registrant remains non-compliant	Yes ⊠ Yes ⊠ Yes ✓ Yes	No □ No □ No □ No □ No
2.1. The complete a) b) c) d) e)	e Registry will have processes in place to make sure that registered ete and accurate. Do Registry staff routinely check all data submitted about a trial for completeness and meaningfulness to ensure that all TRDS fields are populated and comply with the minimum standards? If one or more items in the TRDS submitted for registration are incomplete or not meaningful, do Registry staff contact the Responsible Registrant and attempt to obtain complete and meaningful data? Does the Registry's database system apply automated checking procedures (e.g. range checks, logic rules) to data items to facilitate validity checking? Does the Registry have processes in place for deciding whether to register trials where the Responsible Registrant remains non-compliant with requests to provide complete and meaningful data? Does the Registry undertake regular internal quality control audits to	Yes Yes Yes Yes OPs).	No No No No No These
2.1. The complete a) b) c) d) e)	e Registry will have processes in place to make sure that registered ete and accurate. Do Registry staff routinely check all data submitted about a trial for completeness and meaningfulness to ensure that all TRDS fields are populated and comply with the minimum standards? If one or more items in the TRDS submitted for registration are incomplete or not meaningful, do Registry staff contact the Responsible Registrant and attempt to obtain complete and meaningful data? Does the Registry's database system apply automated checking procedures (e.g. range checks, logic rules) to data items to facilitate validity checking? Does the Registry have processes in place for deciding whether to register trials where the Responsible Registrant remains non-compliant with requests to provide complete and meaningful data? Does the Registry undertake regular internal quality control audits to assess the level of completeness and accuracy of the data collected? e Registry will have documented Standard Operating Procedures (S	Yes Yes Yes Yes OPs).	No No No No No These
2.1. The complete a) b) c) d) e) 2.2. The SOPs verified and a second a second and a second	Do Registry staff routinely check all data submitted about a trial for completeness and meaningfulness to ensure that all TRDS fields are populated and comply with the minimum standards? If one or more items in the TRDS submitted for registration are incomplete or not meaningful, do Registry staff contact the Responsible Registrant and attempt to obtain complete and meaningful data? Does the Registry's database system apply automated checking procedures (e.g. range checks, logic rules) to data items to facilitate validity checking? Does the Registry have processes in place for deciding whether to register trials where the Responsible Registrant remains non-compliant with requests to provide complete and meaningful data? Does the Registry undertake regular internal quality control audits to assess the level of completeness and accuracy of the data collected? Registry will have documented Standard Operating Procedures (Swill be aligned with the International Standards for Clinical Trial Regions to the Registry have written standards for all procedures and processes employed by the registry? These written standards are known as Standard Operating	Yes Yes Yes Yes OPs). istries	No No No No These S. No

International Clinical Trial Registry Platform International Standards for

Clinical Trial Registration?

X









2.3. The Registry will have processes in place to make sure that people and trials exist

2.3.1. Does the Registry make sure that the person registering the trial exists	Vaa	Nia
and that they are the appropriate Responsible Registrant?	Yes	No
and that they are the appropriate itesponsible registrant:	\boxtimes	
2.3.2. Does the Registry make sure that the trial exists?	Yes	No
If yes, please briefly describe what the registry does to make sure that the trial exists.	X	
Verification mails are sent to all site investigators and to the Principal investigator and other contact persons in the trial		
a) Does the Registry obtain written third-party confirmation that a trial exists?	Yes ⊠	No □
If yes, please specify the method of confirmation: Wherever needed DCGI approval document and Ethics committee approval document		
b) Does the Registry display in the trial record:	Yes	No
 a. if the registry has obtained written third party confirmation of the trial's existence, and 	\boxtimes	
 the name of the third party from whom confirmation was received (eg the name of the ethics committee) 		

2.4. The Registry will have a publicly accessible audit trail so that changes made to the WHO TRDS for an individual trial can be tracked.

a)	Does the Registry allow Responsible Registrants to update their registered trial records?	Yes	No
b)	Does the Registry make available a publicly accessible audit trail of any changes to any TRDS items?	Yes	No
c)	Does the Registry have quality control procedures in place to ensure any updated information continues to fulfil the standards for each TRDS item?	Yes ⊠	No □
d)	Does the Registry use the most up-to-date information as the default display?	Yes ⊠	No □
e)	Can the TRDS, as originally registered, be accessed at all times?	Yes ⊠	No □

2.5. The Registry agrees to comply with the International Standards for Clinical Trial Registries (ISCTR).

a)	Does the Registry Administrator have a thorough working knowledge of the operational aspects of their registry?	Yes	No
b)	Is the Registry Administrator committed to ensuring that all Registry staff are familiar with the standards described in the ISCTR?	Yes	No
c)	Are all Registry staff familiar with the contents of the ISCTR?	Yes	No □





3. Accessibility

the end user?

3.1. The Registry will make the <u>WHO TRDS</u> for public at no charge (<i>ICMJE requirement</i>).	all registered trials accessible	e to t	he
a) Does the Registry make the WHO TRDS	items for all studies in their	Yes	No
register (ie the registry database) access	ible online at no charge to		

searched electronically (ICMJE requirement).	triais	то ве
a) Is it possible to search the Registry online using electronic searches of text words and phrases via a simple, single search box?	Yes	No
text words and prifases via a simple, single search box?	\boxtimes	
b) Does the online search allow users to search in at least the condition	Yes	No
field and the intervention field?	\boxtimes	
c) When the results of a trial identified by a search are displayed, are all	Yes	No
items in the WHO TRDS visible?	\boxtimes	
d) Does the online search have an advanced search option?	Yes	No
Note: This is not a requirement and is being asked for information only	\square	П

3.3. The Registry will allow Responsible Registrants to submit a trial for registration at any time of day on any day of the week (24 hours a day, seven days a week).

a)	Is it possible to submit a trial to the registry 24 hours a day, seven (7)	Yes	No
	days a week?	\boxtimes	
b)	If the Registry is planning downtime, does it publish advance notice of downtime at least one (1) week beforehand?	Yes	No
	downlime at least one (1) week beforehand:		

3.4. The Registry will allow their register database to be searched at any time of day on any day of the week (24 hours a day, seven days a week).

any day or the moon (2) means a day; coron days a moon;			
a) Is it possible to search the register online 24 hours a day, 7	days a	Yes	No
week?		\boxtimes	



	International Clinical	Trials
CTRP	International Clinical Registry Platform	

3.5. It is desirable that Registries in the WHO Registry Network also make the WHO TRDS available in the language(s) of the country or countries served by the registry.

a)	Does the Registry accept and/or display trial information in languages others than English?	Yes □	No ⊠
If yes, p	please specify the languages used:		
Only a	nswer the remaining questions in this section if the answer to the above qu	uestion	is yes.
b)	Does the Registry have quality control procedures in place to ensure	Yes	No
	that all translations are accurate?		
c)	Are all TRDS items for all records also available in English?	Yes	No
d)	Are all trial records translated into English by the Responsible	Yes	No
	Registrant checked by registry staff against the non-English submission before being accepted for registration?		
e)	Are all trial records translated by Registry staff checked by at least one	Yes	No
	other staff member?		
f)	If there is a discrepancy in a translation, is the translation checked by	Yes	No
	a third person?		
g)	Does the Registry make users of the Registry aware of who performed	Yes	No
	the translation (the Responsible Registrant or Registry staff) of a registered record?		
h)	If a trial is registered in more than one language then will the Registry	Yes	No
	submit the "Scientific Title", and a language identifier, to the ICTRP		





4. Únambiguous Identification

4.1. The Regis	stry will have in place process	ses to prevent the r	egistration of a sin	gle trial
more than on	nce on their database.			

a)	Does the Registry make sure that a trial that has been submitted for	Yes	No
	registration is not already been included in their register by first searching and checking their own database?	\boxtimes	
b)	Does the Registry have policies and procedures in place to deal with inadvertent duplicate registration of the same trial within their own register?	Yes ⊠	No

4.2 The Registry will facilitate the retrospective linking (or bridging) on the WHO Search Portal of a single trial registered with more than one registry by entering <u>secondary identifiers</u>. This includes the <u>UTN</u>, and the unique identifiers allocated by other registries in the WHO Registry Network.

a)	Does the Registry require responsible Registrants to make an entry in	Yes	No
	the Secondary Identifiers field?	\boxtimes	
b)	If there are no known secondary identifiers, does the Registry require	Yes	No
	Responsible Registrants to enter 'Nil known' in the Secondary	\square	
	Identifiers field?		
c)	Does the Registry require Responsible Registrants to enter a UTN?	Yes	No
	a. The UTN may be entered into either the Secondary Identifiers field or a field designated specifically for collection of the UTN		\boxtimes
	- , ,		
Note: Th	nis is not a requirement and is being asked for information only.		

4.3. It is desirable that Primary Registries will search the ICTRP Search Portal and attempt to determine if the trial has already been registered by another Primary Registry in the WHO Registry Network or an ICMJE approved registry.

a) Does the Registry attempt to determine whether a submitted trial has	Yes	No
been registered in another Primary Registry or an ICMJE approved registry before registration?		
Note: This is not a requirement and is being asked for information only.		





5. Technical Capacity

up data always available.

5.1. The Registry will submit the	WHO TRDS fo	or <u>all</u> records o	n their register,	in English,
to the WHO ICTRP Central Repos	sitory.			

a)	Will (or does) the Registry submit the WHO TRDS items for all records	Yes	No
	on their register, in English, to the WHO ICTRP Central Repository?	\boxtimes	
	Note: If a registry accepts study types other than interventional tiple (i.e. phoenical studies) these must be provided as		
	trials (i.e. observational studies) these must be provided as		
	well.		
b)	Will (or does) the Registry submit records in the format requested by	Yes	No
	the WHO ICTRP (e.g. xml file) at least once per month?	\boxtimes	
c)	Will (or does) the Registry, after the initial data transfer of all records,	Yes	No
	only submit new or updated records each time (rather than the entire		
	data set every time)?	\boxtimes	Ц

5.2. The Registry will have access to a database that is used to store and manage the submitted data.

a)	Does the Registry have access to a database that is used to store and manage the submitted data?	Yes ⊠	No □
b)	Does the Registry use database software and hardware that guarantees reliable access to registered data and data safety at all times?	Yes ⊠	No □

5.	5.3. The Registry will have access to adequate information technology support.				
	a)	97	Yes	No	
		support?	\boxtimes		
	b)	Does the Registry have access to all of the following? a. reliable application, database, backup and mail servers b. good internet connectivity speed c. sound operating systems d. appropriate software for servers, desktops and laptops e. database and web development and maintenance personnel f. other skilled information technology personnel to support these systems, as required	Yes ⊠	No □	
	c) Please briefly describe the Registry's information technology infrastructure document may be submitted separately if necessary), There is an IT scientist available 24/7 for any IT issue, there are serve				

5.4. The Registry will have adequate security and other provisions against data corruption and loss.

 a) Does the Registry have documented procedures for ensuring adequate data security and other provisions to prevent data corruption and loss? 	Yes	No	
	data security and other provisions to prevent data corruption and loss:	\boxtimes	
b)	Does the Registry issue alerts in advance of website downtime?	Yes	No
	please briefly describe how these alerts are circulated and who is sible for circulating them.	\boxtimes	
	ge reflected on CTRI page. The IT Scientist makes sure for ination of any information.		





Yes

No

6. Ádministration and Governance

b) Does the Registry have a letter of support, or other appropriate documentation, from the Ministry of Health or other relevant national or regional agencies?	Yes No ⊠ □
Note: The letters of support must be submitted to the ICTRP Secretariat as part of the application	
 c) From which country (or countries) does the Registry have the reminational (or regional) clinical trial registry? India , Indian Council of Medical Research- NIMS, funded by Minand Family Welfare, Government of India. 	
d) Please specify the name of the national agencies that have given thei Registry: ICMR-National Institute of Medical Statistics, MOHFW, New Delhi	support to the
6.2. The Registry will publicly disclose ownership, governance structur profit status.	e and not-for-
a) Is the Registry managed by a not-for-profit agency?	Yes No ⊠ □
b) Does the Registry publicly disclose its ownership, governance structures and not-for-profit status in a prominent place on the registry's website?	Yes No ⊠ □
c) What is the web address for the page where the ownership, governance and not-for-profit information is displayed?	
https://ctri.nic.in/Clinicaltrials/sect.php	
d) Will the Registry inform the ICTRP immediately if their ownership, governance structures or not-for-profit status change in any way?	Yes No ⊠ □
6.3. The Registry agrees that, should it cease to function, at least the WHO and updated) for all trial records will be transferred to a Primary Registry Network.	
a) Will the Registry transfer at least the WHO TRDS (original and updated) for all trial records to another Primary Registry in the WHO Registry Network if it ceases to function?	Yes No □ ⊠
6.4. The Registry will have a strategy in place ensure the medium sustainability of the registry	to long term
a) Does the Registry have a documented business plan?	Yes No □

6.1. The Registry will have at least a national remit, and the support of government within the country (or region) to act as the Primary Registry for that country or region (defined

as a group of countries and not a group of states within a country).

a) Does the Registry have at least a national remit?





b)	Does the Registry's business plan include strategies to ensure its	Yes	No
	medium to long term sustainability?	\boxtimes	

7. The Trial Registration Data Set (TRDS)

7.1. The Registry will collect and publicly display all items in the WHO Trial Registration Data Set (TRDS)

	Item/Label	Does the reg this data		Does the publicly di data i	splay this
1	Primary Registry and Trial Identifying Number	Yes ⊠	No □	Yes ⊠	No □
2	Date of Registration in Primary Registry	Yes ⊠	No □	Yes ⊠	No □
3	Secondary Identifying Numbers	Yes ⊠	No □	Yes ⊠	No □
4	Source(s) of Monetary or Material Support	Yes ⊠	No □	Yes ⊠	No □
5	Primary Sponsor	Yes ⊠	No	Yes	No □
6	Secondary Sponsor(s)	Yes ⊠	No □	Yes ⊠	No
7	Contact for public queries	Yes ⊠	No □	Yes ⊠	No □
8	Contact for scientific queries	Yes ⊠	No □	Yes ⊠	No □
9	Public title	Yes ⊠	No □	Yes ⊠	No □
10	Scientific title	Yes ⊠	No □	Yes ⊠	No □
11	Countries of Recruitment	Yes ⊠	No □	Yes ⊠	No □
12	Health condition(s) or problem(s) studied	Yes ⊠	No □	Yes ⊠	No □
13	Interventions	Yes ⊠	No □	Yes ⊠	No □
14	Key Inclusion and Exclusion Criteria	Yes ⊠	No	Yes ⊠	No
15	Study type	Yes	No	Yes ⊠	No
16	Date of first enrolment	Yes ⊠	No	Yes ⊠	No □
17	Sample size	Yes	No	Yes ⊠	No
18	Recruitment status	Yes ⊠	No □	Yes ⊠	No □



	Item/Label	Does the reg this data		Does the publicly di data i	splay this
19	Primary Outcome(s)	Yes □	No □	Yes ⊠	No □
20	Key Secondary Outcome(s)	Yes ⊠	No	Yes ⊠	No □
21	Ethics Review	Yes ⊠	No □	Yes □	No ⊠
22	Completion date	Yes ⊠	No □	Yes ⊠	No □
23	Summary Results	Yes □	N □	Yes ⊠	No □
24	IPD sharing statement	Yes ⊠	No □	Yes ⊠	No □

7.2. The Registry may choose to collect and publicly display other data items. It is recommended that registries consider the following optional, additional data items:

Item/Label	Does the regi this data item		Does the reg publicly disp data item?	
Lay Summary / Synopsis	Yes	No	Yes	No
	\boxtimes		\boxtimes	
Approvals	Yes	No	Yes	No
	\boxtimes			\boxtimes
Results links	Yes	No	Yes	No
	\boxtimes			\boxtimes

URL	Yes	No	Yes	No
		\boxtimes		\boxtimes





8. Partner Registries

8.1.	Primary	Registries	in the WF	IO Registry	Network will	have the	capacity	to	partner
with	n other R	egistries.							

a) Is the Registry willing and able to form partnerships with other	Yes	No
Registries that do not themselves fulfil the criteria for a Primary Registry in the WHO Registry Network?		\boxtimes
b) Does the Registry currently have any Partner Registries?	Yes	No
If yes, please provide the name(s) of these partners:		X
c) If the registry has partners, are they listed on the proposed Primary	Yes	No
Registry's web site?		\boxtimes
If yes, please provide the address of this web page:		
Note: A completed Registry Profile form is required for all Partner Registries. This profile will be published on the ICTRP's web site.		

8.2. Primary Registries in the WHO Registry Network will ensure that potential Partner Registries meet WHO minimum standards requirements.

. vog.ot.	noo moot wire minimum otanaarao roquiromonto.			
a)	Does the proposed Primary Registry agree that, before agreeing to accept a Partner Registry and their trial registration records, they will make sure that the Partner Registry meets all the WHO minimum standards listed in the International Standards for Clinical Trial Registries?	Yes	No ⊠	
b)	Has a Registry Profile form been completed and submitted for all of the Registry's Partner Registries?	Yes	No ⊠	

8.3. Primary Registries will have procedures in place to enable exchange of data with Partner Registries.

a) Is the Registry able to accept data (that is, as elect		Yes	No
Partner Registries or other appropriate data providence	ders?		\boxtimes
b) Does the Registry agree to establish a Memorandu		Yes	No
(MOU) or other such agreement with each Partr data providers, as per the requirement described	0 ,		
Standards for Clinical Trial Registries?	an the international		
c) Does the Primary Registry agree the area of cover		Yes	No
their Partner Registries or other data providers (s location, health condition, intervention type, etc)	0 0 .		\boxtimes
into their SOPs and instructions to Registrants to			
or unintentional duplicate registration?			
d) Does the Primary Registry record the identification		Yes	No
registration in the Partner Registry within the trial re	ecord on the Primary		\boxtimes
e) Does the Primary Registry identify records that		Yes	No
from Partner Registries or other data providers so the data source?	o users are aware or		\boxtimes
f) Before announcing Partner Registries, Primary R	<u> </u>	Yes	No
successfully imported data into the Primary Regis	try?		\boxtimes









Administrator

The Administrator is the person employed to manage the Registry and will be the primary point of contact between the Registry and the ICTRP Secretariat.

Title (Dr/Prof/Mr/Mrs/Ms/Miss)	Dr	
Given Name	Vishnu	
Family Name	Vardhana Rao	
Telephone number	+91 11 2658 8803 9849425258	
Fax		
Email	dr_vishnurao@yahoo.com	

Secondary Contact

The Secondary Contact must not be the same as the Administrator. Secondary contact details are requested for circumstances when the Administrator is unavailable.

Title (Dr/Prof/Mr/Mrs/Ms/Miss)	Dr
Given Name	Tulsi
Family Name	Adhikari
Telephone number	+918130511591
Fax	
Email	tulsi_adhikari2003@yahoo.co.in tulsiadhikari@icmr.gov.in

Information Technology Officer

The Information Technology Officer should be the person who will be responsible for submitting the data for inclusion on the ICTRP Central Repository. They should have a good understanding of all of the IT issues relevant to the registry.

Title (Dr/Prof/Mr/Mrs/Ms/Miss)	Mr
Given Name	Yashmin
Family Name	Panchal
Telephone number	9810174898
Fax	
Email	yashupanchal@gmail.com



List of participants of the Review Committee Meeting

Dr Gagandeep Kang, Executive Director, THSTI Faridabad

Dr V.G. Somani, Joint DCGI, CDSCO HQs FDA Bhawan New Delhi

Dr Vishnu Vardhana Rao ICMR-NIMS & Administrator CTRI, New Delhi

Dr Arvind Pandey, Advisor, ICMR - NIMS, New Delhi

Dr Rubina Bose, Deputy Drugs Controller (I), CDSCO HQs, New Delhi

Dr N Srikanth, Deputy Director General, CCRAS, Janakpuri New Delhi

Dr SVS Deo, Professor Dept of Surgical Oncology, IRCH, AIIMS New Delhi

Dr Ashutosh Biswas, Professor Dept of Medicine, AIIMS, New Delhi

Dr Geeta Jotwani, Scientist F ICMR, New Delhi

Dr Sameer Bakshi, Professor, Dept. of Medical Oncology IRCH, AIIMS, New Delhi

Dr Ramesh Agarwal, Professor Dept. of Pediatrics, AIIMS, New Delhi

Dr Vijay Zutshi, Professor Dept. of Obs. & Gynaecology, Safdarjung Hospital, New Delhi